Vor Biopharma VOR Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $169.87M+239% | $396.49M+384% | $160.46M+204% | $190.57M+151% | $50.05M+11.3% | ||
| $321.65M+3,120% | $58.72M+489% | $10M-0.1% | $9.99M+1.3% | $9.99M-84.0% | ||
| $9.79M-42.3% | $7.91M-51.4% | $10.96M-28.0% | $14.42M-1.9% | $16.96M+16.1% | ||
| $500.78M+672% | $458.11M+375% | $172.49M+156% | $204.93M+127% | $64.85M-42.0% | ||
| $565K-90.6% | $533K-91.9% | $271K-96.4% | $0-100% | $5.99M-34.7% | ||
| $2.83M-91.6% | $2.94M-91.6% | $3.04M-91.6% | $24K-99.9% | $33.7M-13.2% | ||
| $2.41M+1.6% | $2.38M0.0% | $269K-89.3% | $420K-86.3% | $2.37M-50.8% | ||
| $506.75M+364% | $464.13M+225% | $176.24M+51.9% | $205.37M+45.0% | $109.31M-34.6% | ||
| $1.04M-72.1% | $5.13M+241% | $885K-32.8% | $669K-66.7% | $3.73M+60.5% | ||
| $14.73M+33,370% | $19.76M+53.3% | $17.7M+136,069% | $58.1M+232,316% | $44K-67.2% | ||
| $307K-92.8% | $280K-93.4% | $252K-93.9% | $0-100% | $4.27M+7.8% | ||
| $16.08M-3.9% | $25.17M+35.2% | $18.84M+31.3% | $58.77M+326% | $16.73M+26.6% | ||
| $2.63M-90.1% | $2.72M-90.2% | $2.81M-90.2% | $0-100% | $26.52M-13.9% | ||
| $2.94M-90.5% | $3M-90.6% | $3.06M-90.7% | $0-100% | $30.78M-11.4% | ||
| $657.17M+1,420% | $628.44M+1,259% | $2.4B+5,481% | $1.71B+3,833% | $43.24M-1.7% | ||
| $19K+46.2% | $18K+38.5% | $15K+114% | $13K+85.7% | $13K+85.7% | ||
| $1.22B+120% | $988.6M+78.6% | $650.32M+30.3% | $557.42M+12.2% | $555.51M+12.5% | ||
| -$1.37B-180% | -$1.15B-152% | -$2.88B-575% | -$2.06B-417% | -$489.48M-32.0% | ||
| -$706K-3,170% | $41K+86.4% | $12K-82.4% | $14K+120% | $23K+126% | ||
| -$150.42M-328% | -$164.31M-70.0% | -$2.23B-3,150% | -$1.51B-1,635% | $66.07M-46.3% | ||
| $506.75M+364% | $464.13M+225% | $176.24M+51.9% | $205.37M+45.0% | $109.31M-34.6% | ||
| $321.65M+3,120% | $58.72M+489% | $10M-0.1% | $9.99M+1.3% | $9.99M-84.0% | ||
| $2.86M+863% | $1.75M+359% | $1.28M+348% | $449K+65.1% | $297K-41.4% | ||
| $2.41M+1.6% | $2.38M0.0% | $269K-89.3% | $420K-86.3% | $2.37M-50.8% | ||
| $2.83M-91.6% | $2.94M-91.6% | $3.04M-91.6% | $24K-99.9% | $33.7M-13.2% | ||
| $2.83M-91.6% | $2.94M-91.6% | $3.04M-91.6% | $24K-99.9% | $33.7M-13.2% | ||
| $2.41M+1.6% | $2.38M0.0% | $269K-89.3% | $420K-86.3% | $2.37M-50.8% | ||
| $2.83M-91.6% | $2.94M-91.6% | $3.04M-91.6% | $24K-99.9% | $33.7M-13.2% | ||
| $2.41M+1.6% | $2.38M0.0% | $269K-89.3% | $420K-86.3% | $2.37M-50.8% | ||
| $14.73M+69.6% | $19.76M+53.3% | $17.7M+100.0% | $58.1M+659% | $8.69M+27.8% | ||
| $14.73M+69.6% | $19.76M+53.3% | $17.7M+100.0% | $58.1M+659% | $8.69M+27.8% | ||
| —— | —— | —— | —— | $30.78M-11.4% | ||
| $1.22B+120% | $988.6M+78.6% | $650.32M+30.3% | $557.42M+12.2% | $555.51M+12.5% | ||
| $19K+46.2% | $18K+38.5% | $15K+114% | $13K+85.7% | $13K+85.7% | ||
| $6.39M+41.6% | $1.15M-72.6% | $747K-82.2% | $1.5M-62.9% | $4.52M+17.9% | ||
| $168K-93.0% | $168K-93.0% | $168K-93.0% | $0-100% | $2.41M0.0% | ||
| $638.46M— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vor Biopharma's total assets?
- Vor Biopharma (VOR) holds $506.7M in total assets, up 363.6% year over year.
- How much debt does Vor Biopharma have?
- Vor Biopharma carries $2.9M in total debt against -$150.4M of shareholders' equity, a debt-to-equity ratio of 0.47.
- How much cash does Vor Biopharma have?
- Vor Biopharma holds $169.9M in cash and equivalents.
- Can Vor Biopharma cover its short-term obligations?
- Its current ratio is 31.15 — current assets exceed current liabilities.
- Where does Vor Biopharma's balance sheet data come from?
- Every line is extracted from Vor Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.